ES2188593T3 - Vacuna que contiene un virus vivo. - Google Patents

Vacuna que contiene un virus vivo.

Info

Publication number
ES2188593T3
ES2188593T3 ES93908381T ES93908381T ES2188593T3 ES 2188593 T3 ES2188593 T3 ES 2188593T3 ES 93908381 T ES93908381 T ES 93908381T ES 93908381 T ES93908381 T ES 93908381T ES 2188593 T3 ES2188593 T3 ES 2188593T3
Authority
ES
Spain
Prior art keywords
virus
avian
human
lyophilization
purifying
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93908381T
Other languages
English (en)
Inventor
Laszlo K Csatary
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
United Cancer Research Institute
Original Assignee
United Cancer Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from HU9200966A external-priority patent/HU207297B/hu
Application filed by United Cancer Research Institute filed Critical United Cancer Research Institute
Application granted granted Critical
Publication of ES2188593T3 publication Critical patent/ES2188593T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/15—Reoviridae, e.g. calf diarrhea virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

UN PROCESO PARA LA PREPARACION DE UNA VACUNA DE VIRUS PURIFICADO COMPRENDE LOS PASOS DE PURIFICAR UN FLUIDO QUE CONTIENE UN VIRUS MEDIANTE CENTRIFUGACION, ULTRACENTRIFUGACION PARA DAR FORMA DE PELOTILLA AL FLOTANTE, PURIFICACION DEL VIRUS MEDIANTE ULTRACENTRIFUGACION DE GRADIENTE DE SACAROSA, REHIDRATACION Y LIOFILIZACION. DESEABLEMENTE, UN ALMIDON MODIFICADO, COMO UN ALMIDON DE HIDROXIETILO QUE TIENE UN PESO MOLECULAR EN EL RANGO DE 100.000-300.000, SE AÑADE COMO UN COLOIDE PROTECTOR ANTES DE LA LIOFILIZACION. EL VIRUS SE SELECCIONA DEL GRUPO QUE CONSTA DE PARAMIXOVIRUS CARACTERISTICO DE LAS AVES, VIRUS DE HERPES DE AVE, BRONQUITIS DE AVE, ENCEFALITIS DE AVE, VIRUS DE BURSITIS DE AVE (GUMBORO), VIRUS DE LA ENFERMEDAD DE MAREK, PARVOVIRUS, VIRUS DE LA ENFERMEDAD DE NEWCASTLE, PARAMIXOVIRUS HUMANO, PARVOVIRUS HUMANO, ADENOVIRUS HUMANO Y MEZCLAS DE LOS MISMOS. UNA VACUNA DE VIRUS PURIFICADO REALIZADA MEDIANTE EL METODO ANTERIOR ES UTIL PARA EL TRATAMIENTO Y CONTROL DE ENFERMEDADES EN MAMIFEROS DE ORIGEN VIRAL.
ES93908381T 1992-03-24 1993-03-23 Vacuna que contiene un virus vivo. Expired - Lifetime ES2188593T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
HU9200966A HU207297B (en) 1992-03-24 1992-03-24 Process for producing 4-hydroxy-7-chloro-quinoline
HU9226547 1992-08-17

Publications (1)

Publication Number Publication Date
ES2188593T3 true ES2188593T3 (es) 2003-07-01

Family

ID=26318074

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93908381T Expired - Lifetime ES2188593T3 (es) 1992-03-24 1993-03-23 Vacuna que contiene un virus vivo.

Country Status (10)

Country Link
EP (1) EP0713397B1 (es)
KR (1) KR950700756A (es)
AT (1) ATE229344T1 (es)
AU (1) AU673827B2 (es)
CA (1) CA2132328C (es)
DE (1) DE69332566T2 (es)
DK (1) DK0713397T3 (es)
ES (1) ES2188593T3 (es)
PT (1) PT713397E (es)
WO (1) WO1993018790A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2161671A1 (en) 1993-04-30 1994-11-10 Robert M. Lorence Methods of treating and detecting cancer using viruses
DE4422238C2 (de) * 1994-06-24 1996-05-30 Behringwerke Ag Verfahren zur Isolierung einer Antigenpräparation
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
WO1998022588A2 (en) 1996-11-20 1998-05-28 Introgen Therapeutics, Inc. An improved method for the production and purification of adenoviral vectors
US20030044384A1 (en) 1997-10-09 2003-03-06 Pro-Virus, Inc. Treatment of neoplasms with viruses
US7470426B1 (en) 1997-10-09 2008-12-30 Wellstat Biologics Corporation Treatment of neoplasms with viruses
US7780962B2 (en) 1997-10-09 2010-08-24 Wellstat Biologics Corporation Treatment of neoplasms with RNA viruses
GB9808922D0 (en) 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
DK1133316T3 (da) * 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
IL145899A0 (en) 1999-04-15 2002-07-25 Pro Virus Inc Treatment of neoplasms with viruses
US8147822B1 (en) 1999-09-17 2012-04-03 Wellstat Biologics Corporation Oncolytic virus
IL148621A0 (en) 1999-09-17 2002-09-12 Pro Virus Inc Oncolytic virus
WO2005066333A1 (en) * 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
EP1708747A2 (en) 2004-01-15 2006-10-11 Intervet International BV Non-animal origin stabilizers and processes for producing the same
AU2005305347A1 (en) 2004-11-03 2006-05-18 Introgen Therapeutics Inc. Method of producing and purifying of adenoviral vectors
HUE031042T2 (en) 2005-07-29 2017-06-28 Abbott Laboratories Gmbh Methods for producing pancreatin powder with low viral content
US9198871B2 (en) 2005-08-15 2015-12-01 Abbott Products Gmbh Delayed release pancreatin compositions
US11266607B2 (en) 2005-08-15 2022-03-08 AbbVie Pharmaceuticals GmbH Process for the manufacture and use of pancreatin micropellet cores
US10072256B2 (en) 2006-05-22 2018-09-11 Abbott Products Gmbh Process for separating and determining the viral load in a pancreatin sample
ES2380289T3 (es) 2009-11-30 2012-05-10 United Cancer Research Institute Nuevo clon del virus de la enfermedad de Newcastle, su fabricación y aplicación en el tratamiento médico del cáncer
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
EP2646051A4 (en) 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
EP4499051A1 (en) * 2022-03-30 2025-02-05 Bioneedle Drug Delivery B.V. A process for storing biologically active constructs in a biodegradable material

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4158054A (en) * 1973-10-18 1979-06-12 Duncan Flockhart & Co. Ltd. Preparation of virus sub-unit vaccines
US3874999A (en) * 1973-10-31 1975-04-01 American Cyanamid Co Process for the purification of virus vaccine
BE853923A (fr) * 1977-04-25 1977-10-25 Rit Rech Ind Therapeut Nouveau vaccin vivant ameliore contre le pseudopeste aviaire et son procede de preparation
US4457916A (en) * 1982-08-31 1984-07-03 Asahi Kasei Kogyo Kabushiki Kaisha Method for stabilizing Tumor Necrosis Factor and a stable aqueous solution or powder containing the same
GB8324800D0 (en) * 1983-09-15 1983-10-19 Pasteur Institut Antigens
HU197846B (en) * 1984-07-02 1989-06-28 Laszlo Csatary Process for producing therapeutic composition suitable for treating virus infections
HU197517B (en) * 1984-07-30 1989-04-28 Laszlo Csatary Process for production of terapeutical composition applicable against virus infection
DD229031A1 (de) * 1984-11-19 1985-10-30 Fi Fuer Lungenkrankheiten Und Verfahren zur herstellung eines oral-impfstoffes
WO1988000980A1 (en) * 1986-08-04 1988-02-11 The United States Of America, As Represented By Th Human b lymphotropic virus (hblv) isolation and products
US4824668A (en) * 1987-03-09 1989-04-25 Sterwin Laboratories Inc. Attenuated infectious bursal disease virus strain and vaccine therefrom
US5124148A (en) * 1988-04-27 1992-06-23 United Cancer Research Institute Method for treating viral diseases with attenuated virus
AU663290B2 (en) * 1990-05-21 1995-10-05 The Administrators Of The Tulane Eductional Fund Association between a human immunodeficiency virus-related retrovirus and Sjogren's syndrome

Also Published As

Publication number Publication date
KR950700756A (ko) 1995-02-20
CA2132328A1 (en) 1993-09-30
WO1993018790A1 (en) 1993-09-30
ATE229344T1 (de) 2002-12-15
AU673827B2 (en) 1996-11-28
EP0713397A1 (en) 1996-05-29
EP0713397A4 (en) 1995-12-07
AU3922293A (en) 1993-10-21
PT713397E (pt) 2003-04-30
EP0713397B1 (en) 2002-12-11
DE69332566D1 (de) 2003-01-23
DE69332566T2 (de) 2003-09-04
CA2132328C (en) 2000-10-31
DK0713397T3 (da) 2003-03-31

Similar Documents

Publication Publication Date Title
ES2188593T3 (es) Vacuna que contiene un virus vivo.
US5192539A (en) Infectious bursal disease virus production in continuous cell lines
US4317811A (en) Herpes simplex type 1 subunit vaccine
DE68915165D1 (de) Schimärische glykoproteine enthaltende immunogenische abschnitte von menschlichem parainfluenzavirus typ 3.
DE3689622D1 (de) Impfstoffe gegen menschliche respiratorische viren.
IL128804A (en) A method for preparing live birnavirus, a live chimeric virus obtained thereby and vaccine comprising said virus
US4302444A (en) Vaccines for immunizing egg-laying birds against Egg Drop disease, preparation of said vaccines, and method of use of said vaccines
Kelly et al. Fowl plague virus replication in mammalian cell-avian erythrocyte heterokaryons: Studies concerning the actinomycin D and ultra-violet light sensitive phase in influenza virus replication
Budowsky et al. Principles of selective inactivation of viral genome. V. Rational selection of conditions for inactivation of the viral suspension infectivity to a given extent by the action of β-propiolactone
DK0626008T3 (da) Vaccine, der som en adjuvans indeholder acemannan
Cox The structural proteins of rabies virus
DZ1550A1 (fr) Vaccin depourvu de cellules contre le virus de la maladie marek.
Carmichael et al. Small-plaque variant of canine herpesvirus with reduced pathogenicity for newborn pups
Sasaki et al. Enhancement of infectivity of cell-free varicella-zoster virus with diethylaminoethyl-dextran
RU2195959C1 (ru) Инактивированная вакцина против синдрома гидроперикардита кур
SASAKI et al. Materials and Methods. Virus strain.
RU2193062C1 (ru) Штамм кр 95 № 114 вируса синдрома гидроперикардита кур для изготовления вакцинных препаратов
MX9702769A (es) Mejoras en una linea de celulas sustentable o estable para la produccion de vacunas para la enfermedad de marek.
RU2199342C1 (ru) Способ изготовления инактивированной вакцины против синдрома гидроперикардита кур
RU2213576C1 (ru) Способ изготовления инактивированной эмульсионной вакцины против синдрома гидроперикардита кур
PAYNE STUDIES ON ACUTE AND LATENT HERPES SIMPLEX VIRUS TYPE 1 INFECTIONS AND THE INFLUENCE OF SERUM IMMUNOGLOBULINS.
Glück et al. New aspects concerning the immunogenicity of rabies vaccines produced in animal brains (duck embryo)
RU94031386A (ru) Вакцина сухая культуральная против вирусного энтерита гусей и способ профилактики и лечения вирусного энтерита гусей
GB916803A (en) Vaccine for the protection of humans against trachoma
Xiaobin et al. Analysis of the Antigens of Detergent Disrupted Bovine Ephemeral Fever Virus